Хайлтын үр дүнгүүд - Hasmann, Max
- 9-н 1 - 9 үр дүнгүүдийг харуулж байна
-
1
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab -н Mamidi, Srinivas, Cinci, Marc, Hasmann, Max, Fehring, Volker, Kirschfink, Michael
Хэвлэсэн 2013текст -
2
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab -н Hughes, Juliana Bentes, Rødland, Marianne Skeie, Hasmann, Max, Madshus, Inger Helene, Stang, Espen
Хэвлэсэн 2012текст -
3
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer -н Collins, Denis, Jacob, Wolfgang, Cejalvo, Juan Miguel, Ceppi, Maurizio, James, Ian, Hasmann, Max, Crown, John, Cervantes, Andrés, Weisser, Martin, Bossenmaier, Birgit
Хэвлэсэн 2017текст -
4
Disentangling ERBB Signaling in Breast Cancer Subtypes—A Model-Based Analysis -н Kemmer, Svenja, Berdiel-Acer, Mireia, Reinz, Eileen, Sonntag, Johanna, Tarade, Nooraldeen, Bernhardt, Stephan, Fehling-Kaschek, Mirjam, Hasmann, Max, Korf, Ulrike, Wiemann, Stefan, Timmer, Jens
Хэвлэсэн 2022текст -
5
Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions -н Schmid, Ingrid, Bonnington, Lea, Gerl, Monika, Bomans, Katrin, Thaller, Anna Louisa, Wagner, Katharina, Schlothauer, Tilman, Falkenstein, Roberto, Zimmermann, Boris, Kopitz, Jürgen, Hasmann, Max, Bauss, Frieder, Haberger, Markus, Reusch, Dietmar, Bulau, Patrick
Хэвлэсэн 2018текст -
6
Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts -н Berdiel-Acer, Mireia, Maia, Ana, Hristova, Zhivka, Borgoni, Simone, Vetter, Martina, Burmester, Sara, Becki, Corinna, Michels, Birgitta, Abnaof, Khalid, Binenbaum, Ilona, Bethmann, Daniel, Chatziioannou, Aristotelis, Hasmann, Max, Thomssen, Christoph, Espinet, Elisa, Wiemann, Stefan
Хэвлэсэн 2021текст -
7
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small... -н Cejalvo, Juan-Miguel, Jacob, Wolfgang, Fleitas Kanonnikoff, Tania, Felip, Enriqueta, Navarro Mendivil, Alejandro, Martinez Garcia, Maria, Taus Garcia, Alvaro, Leighl, Natasha, Lassen, Ulrik, Mau-Soerensen, Morten, Adessi, Celine, Michielin, Francesca, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés
Хэвлэсэн 2019текст -
8
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-... -н Schneeweiss, Andreas, Park-Simon, Tjoung-Won, Albanell, Joan, Lassen, Ulrik, Cortés, Javier, Dieras, Veronique, May, Marcus, Schindler, Christoph, Marmé, Frederik, Cejalvo, Juan Miguel, Martinez-Garcia, Maria, Gonzalez, Iria, Lopez-Martin, Jose, Welt, Anja, Levy, Christelle, Joly, Florence, Michielin, Francesca, Jacob, Wolfgang, Adessi, Céline, Moisan, Annie, Meneses-Lorente, Georgina, Racek, Tomas, James, Ian, Ceppi, Maurizio, Hasmann, Max, Weisser, Martin, Cervantes, Andrés
Хэвлэсэн 2018текст -
9
Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer -н Collins, Denis M., Madden, Stephen F., Gaynor, Nicola, AlSultan, Dalal, Le Gal, Marion, Eustace, Alex J., Gately, Kathy A., Hughes, Clare, Davies, Anthony M., Mahgoub, Thamir, Ballot, Jo, Toomey, Sinead, O’Connor, Darran P., Gallagher, William M., Holmes, Frankie A., Espina, Virginia, Liotta, Lance, Hennessy, Bryan T., O’Byrne, Kenneth J., Hasmann, Max, Bossenmaier, Birgit, O’Donovan, Norma, Crown, John
Хэвлэсэн 2020текст